Literature DB >> 23182058

Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia.

Victoria Mar1, Hugh Roberts2, Rory Wolfe3, Dallas R English4, John W Kelly2.   

Abstract

BACKGROUND: There is a growing body of evidence that nodular melanoma (NM), because of its association with increased growth rate and thickness at diagnosis, accounts for a substantial proportion of melanoma deaths.
OBJECTIVE: We sought to assess the contribution of NM to melanoma deaths in comparison with other tumor subtypes.
METHODS: Four cohorts were established comprising 5775 cases of invasive primary cutaneous melanoma reported to the Victorian Cancer Registry during 1989, 1994, 1999, and 2004. Original pathology reports were reviewed. Age-standardized melanoma incidence rates were compared from 1989 to 2004 with annual percentage change using Poisson regression.
RESULTS: The incidence of thick tumors (>4 mm) increased by 3.8% (95% confidence interval 1.4 to 6.2) and 2.5% (95% confidence interval -0.5 to 5.5) per year for male and female patients, respectively. The median thickness of NM at diagnosis was 2.6 mm compared with 0.6 mm for superficial spreading melanoma. A third of patients who died from melanoma during the follow-up period had thick tumors (>4 mm), most of which were nodular subtype (61%). NM accounted for 14% of invasive melanomas, but was responsible for 43% of melanoma deaths in a total of 57,461 person-years of follow-up. By comparison, superficial spreading melanoma contributed 56% of invasive melanoma but only 30% of deaths. LIMITATIONS: Pathology review was limited to reports only. Mortality information relied mostly on death certificate information.
CONCLUSION: The incidence of thick melanomas continues to increase. Nodular melanoma is clinically distinct and the predominant contributor to melanoma-related deaths, representing a public health challenge in reducing skin cancer mortality.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23182058     DOI: 10.1016/j.jaad.2012.09.047

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

1.  Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Authors:  Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

2.  Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers.

Authors:  Clio Dessinioti; Niki Dimou; Alan C Geller; Aravella Stergiopoulou; Serigne Lo; Ulrike Keim; Jeffrey E Gershenwald; Lauren E Haydu; Simone Ribero; Pietro Quaglino; Susana Puig; Josep Malvehy; Lidija Kandolf-Sekulovic; Tatjana Radevic; Roland Kaufmann; Laura Meister; Eduardo Nagore; Victor Traves; Grigorios G Champsas; Mihaela Plaka; Brigitte Dreno; Emilie Varey; David Moreno Ramirez; Reinhard Dummer; Joanna Mangana; Axel Hauschild; Friederike Egberts; Ketty Peris; Laura Del Regno; Ana-Maria Forsea; Sabina A Zurac; Ricardo Vieira; Ana Brinca; Iris Zalaudek; Teresa Deinlein; Eleni Linos; Evangelos Evangelou; John F Thompson; Richard A Scolyer; Claus Garbe; Alexander J Stratigos
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

3.  The Additive Value of 3D Total Body Imaging for Sequential Monitoring of Skin Lesions: A Case Series.

Authors:  Katarzyna Grochulska; Brigid Betz-Stablein; Chantal Rutjes; Frank Po-Chao Chiu; Scott W Menzies; H Peter Soyer; Monika Janda
Journal:  Dermatology       Date:  2021-08-11       Impact factor: 5.366

4.  Phenotypic Characteristics and Melanoma Thickness in Women.

Authors:  Reza Ghiasvand; Adèle C Green; Torkjel M Sandanger; Elisabete Weiderpass; Trude E Robsahm; Marit B Veierød
Journal:  Acta Derm Venereol       Date:  2021-04-29       Impact factor: 3.875

5.  Clinical Suspicion Sensitivity of Nodular and Superficial Spreading Melanoma.

Authors:  Trude E Robsahm; Per Helsing; Henrik L Svendsen; Marit B Veierød
Journal:  Acta Derm Venereol       Date:  2021-04-12       Impact factor: 3.875

6.  Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study.

Authors:  M Mandalà; P Rutkowski; F Galli; R Patuzzo; V De Giorgi; E Rulli; A Gianatti; B Valeri; B Merelli; A Szumera-Ciećkiewicz; D Massi; A Maurichi; P Teterycz; M Santinami
Journal:  ESMO Open       Date:  2022-04-11

7.  Early Phase of Primary Melanoma Growth from the Patient Point of view: A Prospective Cross Sectional Study on Melanoma over 1 mm in Thickness.

Authors:  Nausicaa Malissen; Safia Abed; Nicolas Macagno; Florent Amatore; Anderson Loundou; Florent Grange; Caroline Gaudy-Marqueste; Jean-Jacques Grob
Journal:  Acta Derm Venereol       Date:  2020-07-28       Impact factor: 3.875

8.  [Thick cutaneous melanoma: mortality factors and occurrence of metastases].

Authors:  Mariam Tarwate; Hakima Benchikhi; Latifa Adarmouch; Abdelatif Benider; Mohamed Amine; Soumya Zamiati; El Hassan Boukind
Journal:  Pan Afr Med J       Date:  2014-05-12

9.  High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry.

Authors:  Trude Eid Robsahm; Per Helsing; Yngvar Nilssen; Linda Vos; Syed Mohammad H Rizvi; Lars A Akslen; Marit B Veierød
Journal:  Clin Epidemiol       Date:  2018-05-09       Impact factor: 4.790

10.  Performance of the "if in doubt, cut it out" rule for the management of nodular melanoma.

Authors:  Elvira Moscarella; Aimilios Lallas; Caterina Longo; Iris Zalaudek; Stefano Caccavale; Alessio Gambardella; Amalia Lupoli; Roberto Alfano; Giuseppe Argenziano
Journal:  Dermatol Pract Concept       Date:  2017-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.